Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT03871829
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Oncology Institute of Hope and Innovation, Tucson, Arizona, United States
🇺🇸American Institute of Research (AIR), Whittier, California, United States
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Other: Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14532
- Registration Number
- NCT03871816
- Locations
- 🇺🇸
Sansum Clinic Pharm, Santa Barbara, California, United States
🇺🇸Central Care Cancer Center, Bolivar, Missouri, United States
🇧🇪Jolimont, Haine-Saint-Paul, La Louviere, Belgium
A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: 14C-JNJ-56136379
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT03864601
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT03842189
- Locations
- 🇸🇪
Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden
🇩🇪Justus-Liebig-Universität Gießen, Kinderherzzentrum, Giessen, Germany
🇳🇱Leiden University Medical Center, Leiden, Netherlands
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection
- Conditions
- H7N9 Subtype of Influenza A Virus
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT03834376
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
- Conditions
- Depressive Disorder, Treatment-Resistant
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT03829579
A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health
- Conditions
- Extraintestinal Pathogenic Escherichia Coli Prevention
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 836
- Registration Number
- NCT03819049
- Locations
- 🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
🇺🇸Optimal Research, Peoria, Illinois, United States
🇺🇸Synexus Clinical Research US Inc, Columbus, Ohio, United States
A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 96
- Registration Number
- NCT03808259
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03802682
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03800550
- Locations
- 🇧🇪
SGS Life Science Services, Antwerpen, Belgium